Sonidegib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09143 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | medulloblastoma with extensive nodularity | KG + DL |
| 2 | xeroderma pigmentosum | KG + DL |
| 3 | annular epidermolytic ichthyosis | KG + DL |
| 4 | epidermolysis bullosa simplex with mottled pigmentation | KG + DL |
| 5 | trichothiodystrophy photosensitive | KG + DL |
| 6 | skin cancer | KG + DL |
| 7 | cutaneous adenocystic carcinoma | KG + DL |
| 8 | benign neoplasm of sweat gland | KG + DL |
| 9 | eccrine carcinoma | KG + DL |
| 10 | obsolete cataract, microcephaly, failure to thrive, kyphoscoliosis syndrome | KG + DL |
| 11 | trichothiodystrophy nonphotosensitive | KG + DL |
| 12 | eccrine sweat gland neoplasm | KG + DL |
| 13 | prostate cancer/brain cancer susceptibility | KG + DL |
| 14 | invasive breast carcinoma | KG + DL |
| 15 | Brenner tumor | KG + DL |
| 16 | prostate leiomyoma | KG + DL |
| 17 | fibroma of prostate | KG + DL |
| 18 | male reproductive organ cancer | KG + DL |
| 19 | benign reproductive system neoplasm | KG + DL |
| 20 | sebocystomatosis | KG + DL |
| 21 | epidermolysis bullosa simplex with circinate migratory erythema | KG + DL |
| 22 | benign prostate phyllodes tumor | KG + DL |
| 23 | steatocystoma multiplex-natal teeth syndrome | KG + DL |
| 24 | KRT14-related epidermolysis bullosa simplex | KG + DL |
| 25 | epidermolysis bullosa simplex with anodontia/hypodontia | KG + DL |
| 26 | epidermolysis bullosa simplex due to BP230 deficiency | KG + DL |
| 27 | nasopharyngeal type undifferentiated carcinoma | KG + DL |
| 28 | epidermolysis bullosa simplex due to exophilin 5 deficiency | KG + DL |
| 29 | melanoma, cutaneous malignant, susceptibility to | KG + DL |
| 30 | salivary gland large cell carcinoma | KG + DL |
| 31 | glottis squamous cell carcinoma | KG + DL |
| 32 | lung occult squamous cell carcinoma | KG + DL |
| 33 | gallbladder adenosquamous carcinoma | KG + DL |
| 34 | rectal cloacogenic carcinoma | KG + DL |
| 35 | external ear basal cell carcinoma | KG + DL |
| 36 | supraglottis squamous cell carcinoma | KG + DL |
| 37 | adenosquamous prostate carcinoma | KG + DL |
| 38 | laryngeal adenoid cystic carcinoma | KG + DL |
| 39 | urethral verrucous carcinoma | KG + DL |
| 40 | kidney carcinoma in situ | KG + DL |
| 41 | gall bladder carcinoma in situ | KG + DL |
| 42 | squamous cell bile duct carcinoma | KG + DL |
| 43 | non-keratinizing sinonasal squamous cell carcinoma | KG + DL |
| 44 | larynx verrucous carcinoma | KG + DL |
| 45 | pancreatic adenosquamous carcinoma | KG + DL |
| 46 | sarcomatoid transitional cell carcinoma | KG + DL |
| 47 | carcinoma of lip | KG + DL |
| 48 | liver carcinoma in situ | KG + DL |
| 49 | eye carcinoma in situ | KG + DL |
| 50 | carcinoma in situ of ureter | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.